Taken together, our findings suggest that regulation of SFMBT2 may provide a new therapeutic strategy to control prostate cancer metastasis as well as being a potential biomarker of metastatic prostate cancer. This evidence concerns the gene SFMBT2 and metastatic prostate carcinoma.